September 23,2020: US biotech firm para Tuesday te koishe ki Pune-based pharmaceutical company Serum Institute of India khan para CodagenixInc’s intranasal COVID-19 vaccine candidate olabole shuru kurishe.
Codagenix, investors Adjuvant Capital and TopSpin Partners world’s largest vaccine maker logote milaikena CDX-005 bonabole ase kuntu fruitful results dikhaishe preclinical animal studies te.
“Preclinical testing single, intranasal dose CDX-005 animal klhan uporte bhal safety aro effective signals khan paishe aro etu logote Serum Institute’s financial and technical support logote ami khan etu vaccine toh olabole bhabona kuri ase 2020 khotom nohoa akhe te.”
Company khan bhabona kuri ase Phase 1 clinical trial shuru kuribole nimete COVID-19 vaccine United Kingdom te etu sal shuru nakura akhe te.
Coleman aro koishe ki CDX-005 toh intranasally te injection par a nohoikena kuntu para more efficient, patient-friendly administration kuribole deh.
Tai koishe “CDX-005 toh bona toh ami khan laga proprietary codon deoptimization software platform, chulaikena kuntu para ami khan ke allow kurishe etu SARS-CoV-2 virus laga genome toh recode kuribole nimete mutations khan hundreds nishena halikena.etu mutations results toh live-attenuated vaccine non-pathogenic thaka toh potential thakishe robust tcell stimulate kuribole nimete aro antibody immune response etu wild type virus nimete”.
Coleman aro bi koishe etu Codagenix’slive-attenuated vaccine approach toh sharp contrast te thakishe more common COVID-19 immunization strategies nimete etia human testing jai thaka toh etu te as mRNA or virus-like-particle candidates, kuntu para spike protein target kurishe nohoile toh adenovirus vectored approaches kuntu par a off-target effects te dikdaar dishe.
Review Committee on Genetic Manipulation (RCGM) of India’s Department of Biotechnology (DBT) para approval paa pichede ), Serum Institute khan para large-scale safety and efficacy studies, olabo etu logote tayar kuribhole nimete global vaccine supply requirements khan nimete.
